Ya-Hui Chiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ya-Hui Chiu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Christopher T. Ritchlin
Center for Musculoskeletal Research University of Rochester Medical Center Rochester New York
4 shared publications - Edward M. Schwarz
Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York
3 shared publications - Changyong Feng
University of Rochester
2 shared publications - Kofi A. Mensah
Section of Rheumatology, Allergy, and Clinical Immunology, Yale University School of Medicine, New Haven, CT 06511, USA
2 shared publications - Baoli Wang
Hormones and Development, Metabolic Diseases Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China
1 shared publication - Ben Panepento
Allergy/Immunology & Rheumatology Division, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA
1 shared publication
Latest Publications
- 10 October 2016
- Published by Wiley in Journal of Cellular Physiology
- Vol. 232 (9) , 2538-2549
Dendritic Cell‐Specific Transmembrane Protein (DC‐STAMP) Regulates Osteoclast Differentiation via the Ca2+/NFATc1 Axis
DC‐STAMP is a multi‐pass transmembrane protein essential for cell–cell fusion between osteoclast precursors during osteoclast (OC) development. DC‐STAMP−/− mice have mild osteopetrosis and form mononuclear cells with limited resorption capacity. The identification of an Immunoreceptor Tyrosine‐based Inhibitory Motif (ITIM) on the cytoplasmic tail of DC‐STAMP suggested a potential signaling function. The absence of a known DC‐STAMP ligand, however, has hindered the elucidation of downstream signaling pathways. To address this problem, we engineered a light‐activatable DC‐STAMP chimeric molecule in which light exposure mimics ligand engagement that can be traced by downstream Ca2+ signaling. Deletion of the cytoplasmic ITIM resulted in a significant elevation in the amplitude and duration of intracellular Ca2+ flux. Decreased NFATc1 expression in DC‐STAMP−/− cells was restored by DC‐STAMP over‐expression. Multiple biological phenotypes including cell–cell fusion, bone erosion, cell mobility, DC‐STAMP cell surface distribution, and NFATc1 nuclear translocation were altered by deletion of the ITIM and adjacent amino acids. In contrast, mutations on each of the tyrosine residues surrounding the ITIM showed no effect on DC‐STAMP function. Collectively, our results suggest that the ITIM on DC‐STAMP is a functional motif that regulates osteoclast differentiation through the NFATc1/Ca2+ axis. J. Cell. Physiol. 232: 2538–2549, 2017.
- 10 October 2016
- Published by Wiley in Journal of Cellular Physiology
- Vol. 232 (9) , 2538-2549
Dendritic Cell‐Specific Transmembrane Protein (DC‐STAMP) Regulates Osteoclast Differentiation via the Ca2+/NFATc1 Axis
DC‐STAMP is a multi‐pass transmembrane protein essential for cell–cell fusion between osteoclast precursors during osteoclast (OC) development. DC‐STAMP−/− mice have mild osteopetrosis and form mononuclear cells with limited resorption capacity. The identification of an Immunoreceptor Tyrosine‐based Inhibitory Motif (ITIM) on the cytoplasmic tail of DC‐STAMP suggested a potential signaling function. The absence of a known DC‐STAMP ligand, however, has hindered the elucidation of downstream signaling pathways. To address this problem, we engineered a light‐activatable DC‐STAMP chimeric molecule in which light exposure mimics ligand engagement that can be traced by downstream Ca2+ signaling. Deletion of the cytoplasmic ITIM resulted in a significant elevation in the amplitude and duration of intracellular Ca2+ flux. Decreased NFATc1 expression in DC‐STAMP−/− cells was restored by DC‐STAMP over‐expression. Multiple biological phenotypes including cell–cell fusion, bone erosion, cell mobility, DC‐STAMP cell surface distribution, and NFATc1 nuclear translocation were altered by deletion of the ITIM and adjacent amino acids. In contrast, mutations on each of the tyrosine residues surrounding the ITIM showed no effect on DC‐STAMP function. Collectively, our results suggest that the ITIM on DC‐STAMP is a functional motif that regulates osteoclast differentiation through the NFATc1/Ca2+ axis. J. Cell. Physiol. 232: 2538–2549, 2017.
- 27 March 2016
- Published by Wiley in Journal of Cellular Physiology
- Vol. 231 (11) , 2402-2407
DC-STAMP: A Key Regulator in Osteoclast Differentiation
Osteoimmunology research is a new emerging research field that investigates the links between the bone and immune responses. Results from osteoimmunology studies suggest that bone is not only an essential component of the musculoskeletal system, but is also actively involved in immune regulation. Many important factors involved in immune regulation also participate in bone homeostasis. Bone homeostasis is achieved by a coordinated action between bone‐synthesizing osteoblasts and bone‐degrading osteoclasts. An imbalanced action between osteoblasts and osteoclasts often results in pathological bone diseases: osteoporosis is caused by an excessive osteoclast activity, whereas osteopetrosis results from an increased osteoblast activity. This review focuses on dendritic cell‐specific transmembrane protein (DC‐STAMP), an important protein currently considered as a master regulator of osteoclastogenesis. Of clinical relevance, the frequency of circulating DC‐STAMP+ cells is elevated during the pathogenesis of psoriatic diseases. Intriguingly, recent results suggest that DC‐STAMP also plays an imperative role in bone homeostasis by regulating the differentiation of both osteoclasts and osteoblasts. This article summarizes our current knowledge on DC‐STAMP by focusing on its interacting proteins, its regulation on osteoclastogenesis‐related genes, its possible involvement in immunoreceptor tyrosine‐based inhibitory motif (ITIM)‐mediated signaling cascade, and its potential of developing therapeutics for clinical applications. J. Cell. Physiol. 231: 2402–2407, 2016.
- 27 March 2016
- Published by Wiley in Journal of Cellular Physiology
- Vol. 231 (11) , 2402-2407
DC-STAMP: A Key Regulator in Osteoclast Differentiation
Osteoimmunology research is a new emerging research field that investigates the links between the bone and immune responses. Results from osteoimmunology studies suggest that bone is not only an essential component of the musculoskeletal system, but is also actively involved in immune regulation. Many important factors involved in immune regulation also participate in bone homeostasis. Bone homeostasis is achieved by a coordinated action between bone‐synthesizing osteoblasts and bone‐degrading osteoclasts. An imbalanced action between osteoblasts and osteoclasts often results in pathological bone diseases: osteoporosis is caused by an excessive osteoclast activity, whereas osteopetrosis results from an increased osteoblast activity. This review focuses on dendritic cell‐specific transmembrane protein (DC‐STAMP), an important protein currently considered as a master regulator of osteoclastogenesis. Of clinical relevance, the frequency of circulating DC‐STAMP+ cells is elevated during the pathogenesis of psoriatic diseases. Intriguingly, recent results suggest that DC‐STAMP also plays an imperative role in bone homeostasis by regulating the differentiation of both osteoclasts and osteoblasts. This article summarizes our current knowledge on DC‐STAMP by focusing on its interacting proteins, its regulation on osteoclastogenesis‐related genes, its possible involvement in immunoreceptor tyrosine‐based inhibitory motif (ITIM)‐mediated signaling cascade, and its potential of developing therapeutics for clinical applications. J. Cell. Physiol. 231: 2402–2407, 2016.
- Open Access
- 10 October 2011
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 27 (1) , 79-92
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Osteoclasts (OC) are bone‐resorbing, multinucleated cells that are generated via fusion of OC precursors (OCP). The frequency of OCP is elevated in patients with erosive inflammatory arthritis and metabolic bone diseases. Although many cytokines and cell surface receptors are known to participate in osteoclastogenesis, the molecular mechanisms underlying the regulation of this cellular transformation are poorly understood. Herein, we focused our studies on the dendritic cell‐specific transmembrane protein (DC‐STAMP), a seven‐pass transmembrane receptor‐like protein known to be essential for cell‐to‐cell fusion during osteoclastogenesis. We identified an immunoreceptor tyrosine‐based inhibitory motif (ITIM) in the cytoplasmic tail of DC‐STAMP, and developed an anti‐DC‐STAMP monoclonal antibody 1A2 that detected DC‐STAMP expression on human tumor giant cells, blocked OC formation in vitro, and distinguished four patterns of human PBMC with a positive correlation to OC potential. In freshly isolated monocytes, DC‐STAMPhigh cells produced a higher number of OC in culture than DC‐STAMPlow cells and the surface expression of DC‐STAMP gradually declined during osteoclastogenesis. Importantly, we showed that DC‐STAMP is phosphorylated on its tyrosine residues and physically interacts with SHP‐1 and CD16, an SH2‐domain‐containing tyrosine phosphatase and an ITAM‐associated protein, respectively. Taken together, these data show that DC‐STAMP is a potential OCP biomarker in inflammatory arthritis. Moreover, in addition to its effect on cell fusion, DC‐STAMP dynamically regulates cell signaling during osteoclastogenesis. © 2012 American Society for Bone and Mineral Research
- 10 October 2011
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 27 (1) , 79-92
Open AccessRegulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
Osteoclasts (OC) are bone‐resorbing, multinucleated cells that are generated via fusion of OC precursors (OCP). The frequency of OCP is elevated in patients with erosive inflammatory arthritis and metabolic bone diseases. Although many cytokines and cell surface receptors are known to participate in osteoclastogenesis, the molecular mechanisms underlying the regulation of this cellular transformation are poorly understood. Herein, we focused our studies on the dendritic cell‐specific transmembrane protein (DC‐STAMP), a seven‐pass transmembrane receptor‐like protein known to be essential for cell‐to‐cell fusion during osteoclastogenesis. We identified an immunoreceptor tyrosine‐based inhibitory motif (ITIM) in the cytoplasmic tail of DC‐STAMP, and developed an anti‐DC‐STAMP monoclonal antibody 1A2 that detected DC‐STAMP expression on human tumor giant cells, blocked OC formation in vitro, and distinguished four patterns of human PBMC with a positive correlation to OC potential. In freshly isolated monocytes, DC‐STAMPhigh cells produced a higher number of OC in culture than DC‐STAMPlow cells and the surface expression of DC‐STAMP gradually declined during osteoclastogenesis. Importantly, we showed that DC‐STAMP is phosphorylated on its tyrosine residues and physically interacts with SHP‐1 and CD16, an SH2‐domain‐containing tyrosine phosphatase and an ITAM‐associated protein, respectively. Taken together, these data show that DC‐STAMP is a potential OCP biomarker in inflammatory arthritis. Moreover, in addition to its effect on cell fusion, DC‐STAMP dynamically regulates cell signaling during osteoclastogenesis. © 2012 American Society for Bone and Mineral Research
- Open Access
- 26 January 2010
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 12 (1) , R14
CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis
Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterized by bone erosion mediated by osteoclasts (OC). Our previous studies showed an elevated frequency of OC precursors (OCP) in PsA patients. Here, we examined if OC arise from CD16-positive monocytes in PsA. Methods: Peripheral blood mononuclear cells (PBMC) or monocytes were isolated from human peripheral blood and sorted based on CD16 expression. Sorted cells were cultured alone or with bone wafers in the presence of receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Enumeration and bone erosion activity of OC were examined after culture. The effects of tumor necrosis factor-alpha (TNFα), OC-promoting (M-CSF plus RANKL), and dendritic cell (DC)-promoting (GM-CSF plus interleukin (IL)-4) cytokines on CD16 surface expression were examined by flow cytometry. Results: PsA and psoriasis (Ps) subjects had a higher percentage of circulating inflammatory CD14+CD16+ cells than healthy controls (HC). Exposure of cells to OC-promoting, but not DC-promoting media, was associated with CD16 up-regulation. PBMC of Ps and PsA had a higher frequency of cells expressing intermediate levels of CD16. OC were mainly derived from CD16+ cells in PsA. Increased CD16 expression was associated with a higher bone erosion activity in PsA. Conclusions: An increased frequency of circulating CD14+CD16+ cells was noted in PsA compared to controls, and intermediate levels of CD16 may suggest a transitional state of OCP during osteoclastogenesis. Intriguingly, TNFα blocked CD16 expression on a subset of CD14+ monocytes. Collectively, our data suggest that CD16 has the potential to serve as an OCP marker in inflammatory arthritis.
- 26 January 2010
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 12 (1) , R14
Open AccessCD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis
Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterized by bone erosion mediated by osteoclasts (OC). Our previous studies showed an elevated frequency of OC precursors (OCP) in PsA patients. Here, we examined if OC arise from CD16-positive monocytes in PsA. Methods: Peripheral blood mononuclear cells (PBMC) or monocytes were isolated from human peripheral blood and sorted based on CD16 expression. Sorted cells were cultured alone or with bone wafers in the presence of receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Enumeration and bone erosion activity of OC were examined after culture. The effects of tumor necrosis factor-alpha (TNFα), OC-promoting (M-CSF plus RANKL), and dendritic cell (DC)-promoting (GM-CSF plus interleukin (IL)-4) cytokines on CD16 surface expression were examined by flow cytometry. Results: PsA and psoriasis (Ps) subjects had a higher percentage of circulating inflammatory CD14+CD16+ cells than healthy controls (HC). Exposure of cells to OC-promoting, but not DC-promoting media, was associated with CD16 up-regulation. PBMC of Ps and PsA had a higher frequency of cells expressing intermediate levels of CD16. OC were mainly derived from CD16+ cells in PsA. Increased CD16 expression was associated with a higher bone erosion activity in PsA. Conclusions: An increased frequency of circulating CD14+CD16+ cells was noted in PsA compared to controls, and intermediate levels of CD16 may suggest a transitional state of OCP during osteoclastogenesis. Intriguingly, TNFα blocked CD16 expression on a subset of CD14+ monocytes. Collectively, our data suggest that CD16 has the potential to serve as an OCP marker in inflammatory arthritis.